Navigation Links
DFH Pharma to Collaborate With National Cancer Institute to Develop Second-Generation HIV Maturation Inhibitor Drugs
Date:1/10/2012

GAITHERSBURG, Md., Jan. 10, 2012 /PRNewswire-iReach/ -- DFH Pharma, Inc., (DFH) a privately held specialty pharmaceutical company focused exclusively in the HIV-1 therapeutic space, announced today a collaborative agreement between DFH and the National Cancer Institute (NCI) to further the development of the next generation of HIV maturation inhibitor drugs. Maturation inhibitors are a novel class of antiretroviral drug candidates that inhibit HIV-1 replication by interfering with the maturation of the HIV-1 virus.

The collaboration will involve extending successful efforts by DFH Pharma to identify drug candidates with potent activity against all HIV strains, including those that proved resistant to the first-in-class maturation inhibitor, bevirimat. DFH scientists have identified a series of 2nd generation maturation inhibitors with the broad anti-viral activity profile necessary for successful HIV drug development. The NCI investigators will evaluate the activity of these compounds against HIV strains associated with reduced bevirimat activity. The most potent of these compounds will be selected for further pre-clinical testing with a goal of initiating human clinical trials with one or more candidate molecules in the near future.

Dr. Eric Freed, an internationally recognized leader in the field of HIV assembly and release, will head the NCI group. Dr. Freed has worked in the maturation inhibition area since the early 2000's when his group collaborated with Panacos Pharmaceuticals in the discovery and characterization of the maturation inhibitor class of HIV drugs. "We are very excited to be working with Dr. Freed and his NCI colleagues in developing this new class of drugs to treat HIV infection"' said Carl Wild, Ph.D., President and CEO. Dr. Wild continued, "The NCI collaboration will allow DFH to build on its recent success in identifying broadly active maturation inhibitor drug can
'/>"/>

SOURCE DFH Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
2. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
3. Reata Pharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference
4. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
5. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
6. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
7. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
11. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Shimadzu Scientific Instruments today ... UV-visible spectrophotometer. Offering wavelength scanning from 190 to ... for applications in a variety of industries, including ... user-friendly UV-1280 enables intuitive operation, while the enhanced ...
(Date:1/22/2015)... 2015 Cambridge Semantics, the leading provider of ... that 2014 was a record-breaking year across the board for ... Anzo Smart Data Platform and our Smart Data solutions, our ... diverse data which led to record growth for the company ...
(Date:1/22/2015)... Diego, California (PRWEB) January 22, 2015 ... Promotional Offer to their comprehensive portfolio of Eppendorf ... allows customers to purchase a Centrifuge 5424/5424 R and ... Bundle of either Eppendorf Research plus or Eppendorf Reference ...
(Date:1/22/2015)... 2015 Selexis SA, a serial innovation ... Banks (RCBs) used for drug discovery to commercial manufacturing, ... include Next-Generation Sequencing (NGS) data packages. The ... manufacturing by ensuring the integrity of the gene, validation ...
Breaking Biology Technology:Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Cambridge Semantics Announces Record Results for 2014 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2
... July 11 Sigma-Aldrich Corporation,(Nasdaq: SIAL ), ... second,quarter results on Wednesday, July 23, 2008, at ... This call is being webcast by Thomson/CCBN and ... http://www.sigma-aldrich.com ., The webcast is also ...
... Research Inc., (TSX:,ARI), a biotechnology company discovering ... today announced its financial and operational,results for ... May 31st, 2008., "Throughout the second ... anti-cancer antibodies towards human clinical trial. Most ...
... newly developed nano-sized electronic device is an important step ... creation of the universe. This invisible light makes up ... and may provide insights into the earliest stages of ... , The tiny, new circuit, developed by physicsts at ...
Cached Biology Technology:Sigma-Aldrich Corporation's 2nd Quarter 2008 Earnings Conference Call 2ARIUS announces second quarter fiscal 2008 financial results 2ARIUS announces second quarter fiscal 2008 financial results 3ARIUS announces second quarter fiscal 2008 financial results 4ARIUS announces second quarter fiscal 2008 financial results 5ARIUS announces second quarter fiscal 2008 financial results 6ARIUS announces second quarter fiscal 2008 financial results 7ARIUS announces second quarter fiscal 2008 financial results 8ARIUS announces second quarter fiscal 2008 financial results 9ARIUS announces second quarter fiscal 2008 financial results 10ARIUS announces second quarter fiscal 2008 financial results 11ARIUS announces second quarter fiscal 2008 financial results 12ARIUS announces second quarter fiscal 2008 financial results 13ARIUS announces second quarter fiscal 2008 financial results 14ARIUS announces second quarter fiscal 2008 financial results 15Nano-sized electronic circuit promises bright view of early universe 2Nano-sized electronic circuit promises bright view of early universe 3
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology used for ... overall facial feature of a person such as nose, ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ...
(Date:12/10/2014)... CIE San Diego has launched an innovative trust network ... care coordination among social service and care providers by enabling ... million grant from the Alliance Healthcare Foundation to expand to ... as a "Live Well San Diego" partner on December 11 ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... Survey is partnering with the Chilean government to develop a ... after the historic eruption of Chaitn Volcano on May 2. ... install monitoring networks at Chaitn to transmit data in real ... June 13, the USGS signed a letter of intent with ...
... Northwestern University biomedical engineer who has developed optical technology ... colon cancer has received a $7.5 million grant over ... study an instrument that potentially could become a routine ... trials. Colon cancer is the second-leading cause of ...
... release is available in German . , ... or dissolved metallic salts in high concentrations are detrimental to ... Such conditions destroy proteins, ensuring that all biological functions in ... find at the limits of hostile conditions where we still ...
Cached Biology News:USGS to help Chile develop volcano early warning system 2NCI grant launches clinical trials for colon cancer screening 2NCI grant launches clinical trials for colon cancer screening 3Purple extremist thrives under inhospitable conditions 2Purple extremist thrives under inhospitable conditions 3
... reagent (F-2902) was developed in collaboration with ... measurement of the kinetics of Fc receptor ... directly in the phagovacuole.2 The Fc OxyBURST ... albumin (BSA) that has been covalently linked ...
Because it is manufactured at our ISO 9001–certified facilities in Eugene, Oregon, we can guarantee that FluoroPure grade propidium iodide is greater than or equal to 98% pure by HPLC....
MOUSE ANTI RABBIT T LYMPHOCTYES Immunogen: Rabbit Thymocytes...
TACS Apoptotic DNA Laddering Kits are used to assay cells and tissues for apoptosis by...
Biology Products: